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Abstract 
Background 
Oral squamous cell carcinoma (OSCC) is a global healthcare problem associated 
with poor patient outcomes. Early detection is key to improving patient survival. 
OSCC may be preceded by clinically-recognisable lesions, termed oral potentially 
malignant disorders (OPMD). As histological assessment of OPMD does not 
accurately predict their clinical behaviour, biomarkers are required to detect cases at 
risk of malignant transformation. Epidermal growth factor receptor gene copy number 
(EGFR GCN) is a validated biomarker in lung non-small cell carcinoma. We 
examined EGFR GCN in OPMD and OSCC to determine its potential as a biomarker 
in oral carcinogenesis. 
Methods 
EGFR GCN was examined by in situ hybridisation (ISH) in biopsies from 78 patients 
with OPMD and 92 patients with early-stage (stages I and II) OSCC. EGFR ISH 
signals were scored by two pathologists and a category assigned by consensus. The 
data were correlated with patient demographics and clinical outcomes. 
Results 
OPMD with abnormal EGFR GCN were more likely to undergo malignant 
transformation than diploid cases. EGFR genomic gain was detected in a quarter of 
early-stage OSCC, but did not correlate with clinical outcomes. 
Conclusion 
These data suggest that abnormal EGFR GCN has clinical utility as a biomarker for 
the detection of OPMD destined to undergo malignant transformation. Prospective 
studies are required to verify this finding. It remains to be determined if EGFR GCN 
could be used to select patients for EGFR-targeted therapies. 
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Impact 
Abnormal EGFR GCN is a potential biomarker for identifying OPMD that are at risk 
of malignant transformation. 
(Word count – 248/250)  
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Introduction 
Oral squamous cell carcinoma (OSCC) is a major healthcare problem and is 
associated with poor clinical outcomes. Approximately 50% of patients diagnosed 
with OSCC die prematurely as a consequence of the disease (1, 2). Outcomes for 
patients with OSCC may be improved if the disease is identified in its earliest stages 
(3). OSCC formation occurs through the stepwise accumulation of genetic damage 
(4, 5). OSCC may be preceded by clinically-recognisable lesions termed oral 
potentially malignant disorders (OPMD) (6). However, the histological features of 
OPMD do not reliably predict their clinical behaviour (7, 8). There is consequently a 
need to develop biomarkers that enhance prognostication and direct treatment (9). 
Epidermal growth factor receptor (EGFR) gene copy number (GCN) is used in the 
prognostication of non-small cell lung carcinoma (10, 11) and the prediction of its 
response to EGFR-targeted chemotherapeutic agents (12). The potential of EGFR 
as a biomarker in OSCC was first highlighted in the early 1990s (13). EGFR is a cell 
surface tyrosine kinase receptor, one of four proteins in the ErbB family, and is 
expressed in most epithelial tissues (14). Binding of growth factors (e.g. epidermal 
growth factor and transforming growth factor-α) to the extracellular domain induces a 
conformational change in the internal receptor (15, 16). Subsequent phosphorylation 
of intracellular substrates triggers a myriad of downstream signalling cascades (17). 
In OSCC, these contribute to an increase in cell proliferation, angiogenesis, invasion, 
and metastasis, which are the hallmarks of cancer (18, 19). 
EGFR genomic gain is associated with poor clinical outcomes in OSCC (20-22). The 
prevalence of EGFR genomic gain in OSCC ranges from 9% to 56% (23-26) and is 
more frequent in Stage III/IV disease, suggesting that EGFR genomic gain is a late 
event in oral carcinogenesis. By contrast, data from two OPMD studies show that 
cases with low polysomy are more likely to progress to OSCC (27, 28). These data 
suggest that EGFR GCN starts to increase in the early stages of oral carcinogenesis 
and raise the possibility that it could be used as a biomarker of malignant 
transformation. However, both studies were limited by small samples sizes and 
analysis of tissue microarrays rather than whole sections. Furthermore, low 
polysomy is not regarded as EGFR genomic gain in the criteria currently validated 
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for interpretation of non-small cell lung carcinoma as only high polysomy/clustered 
EGFR GCN signals are reported to correlate significantly with clinical outcome and 
response to EGFR-targeted therapy (10, 11). Consequently, the biological 
significance of EGFR low polysomy is uncertain, particularly given the complexity of 
the EGFR signalling pathway (29, 30). 
The aims of this study were: 
• to determine the frequency of EGFR GCN abnormalities in patients with 
OPMD and early-stage OSCC. 
• to correlate EGFR GCN abnormalities with clinico-pathological data and 
patients’ clinical outcomes. 
• to determine EGFR protein expression in OPMD and early-stage OSCC in 
order to gauge the likely functional significance of EGFR GCN changes. 
Materials and Methods 
Patients 
Cases of OPMD that did not transform to OSCC were identified from a group of 
patients attending a hospital-based OPMD clinic. These cases had a minimum of 24 
months’ follow up. 
Cases of OPMD that underwent malignant transformation were identified using a 
systematic search of the electronic archives using SNOMED codes. The search 
spanned a 12-year period (1997 - 2009). The subsequent OSCC was also identified 
and retrieved for analysis. Clinical follow-up data were obtained from medical 
records. 
Consecutive local cases of early-stage (pStage I/II) OSCC were identified by 
searching hospital databases and latterly the DAHNO (DAta on Head and Neck 
Oncology) UK database. The search spanned an 8-year period (2000 - 2008). 
Cases with the following characteristics were excluded: 1) previous upper aero-
digestive tract cancer; 2) previous radiotherapy to the head and neck region; 3) index 
lesions arising on the lip or in the oropharynx; 4) <24 months’ follow-up; 5) <6 
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months between index OPMD biopsy and OSCC diagnosis; 6) proliferative 
verrucous leukoplakia; 7) non-dysplastic OPMD diagnosed with specific clinico-
pathological entities, e.g. chronic hyperplastic candidosis and lichen planus. 
For each case, patient demographic data (sex, age at first biopsy) and mucosal 
subsite of the OPMD/OSCC were recorded. For OPMD, the clinical outcome (i.e. 
whether or not the lesion underwent malignant transformation to OSCC) was 
recorded. For OPMD that underwent malignant transformation, time from diagnosis 
of OPMD to developing OSCC was calculated. For early-stage OSCC, the 
histological grade of differentiation (Broders’ classification) was determined and 
clinical outcomes (disease-free survival, overall survival) were calculated. 
Pathology methods 
Haematoxylin and eosin (H&E) stained sections and formalin-fixed paraffin-
embedded tissue blocks were retrieved for each case to confirm the presence of 
disease and adequacy of material for subsequent analysis. For OPMD epithelial 
dysplasia was graded independently by two pathologists (MR & PS) using a binary 
system (low-grade vs. high-grade) (7, 8). Discordant cases were reviewed and a 
grade was assigned by consensus. 
EGFR in situ hybridisation 
EGFR GCN was assessed by a dual-colour in situ hybridisation (ISH) technique 
using proprietary reagents (INFORM EGFR-Chromosome 7 dual colour assay, 
Ventana Medical Systems Inc, USA). This detects the EGFR gene (using silver ISH, 
seen as black nuclear dots) and chromosome 7 centromeres (using Ultraview 
Alkaline Phosphatase Red ISH, seen as red nuclear dots) on the same section. 4 µm 
sections were stained using the Ventana Benchmark Autostainer according to the 
manufacturer’s instructions. Negative controls (with DNA probes omitted) were 
performed for each staining batch. 
Dual-stained ISH sections were examined by two pathologists (TB & MR) and a 
category was assigned by consensus. According to the predominant nuclear signal, 
each case was assigned to one of the six categories described and validated by the 
manufacturers for the interpretation of non-small cell lung carcinoma (Figure 1) (31). 
Dividing cells and overlapping cells were not assessed. During analyses, the six 
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descriptive categories were reduced to three groups for comparison: normal, low 
polysomy, and genomic gain (Figure 1) and also analysed in a binary classification: 
normal vs. abnormal EGFR GCN. 
EGFR immunohistochemistry 
EGFR protein expression was detected using a proprietary antibody (anti-EGFR 5B7 
clone, Ventana Medical Systems Inc, USA). 4 µm sections were stained using a 
Ventana Benchmark Autostainer according to the manufacturer’s instructions. 
Morphologically normal epithelium provided an internal control for each section. 
Negative controls (primary antibody omitted) were performed for each staining batch. 
EGFR-stained slides and corresponding H&E sections were scanned using the 
Aperio Scanscope platform (x400 magnification). Files were uploaded to and 
analysed using the Aperio Spectrum image analysis system (Spectrum Version 
11.1.0.751, Aperio Technologies, Inc.). H&E sections were used to map areas of 
normal epithelium, epithelial dysplasia and OSCC on corresponding EGFR-stained 
section. Representative areas were annotated and analysed using the Aperio cellular 
algorithm. The algorithm generated data for a range of parameters including the 
number of cells analysed, the proportion of positive cells, and the proportion of 
strongly-positive cells. Data were collated in an Excel file prior to statistical analysis. 
Statistical analysis 
Statistical analysis was performed using SPSS for Windows (version 21.0; SPSS 
Inc., Chicago, Illinois, USA). Following a test of normality, parametric data were 
analysed using one-way ANOVA/independent sample T-tests, and non-parametric 
data using Kruskal–Wallis/Mann-Whitney U-tests. A Bonferroni correction was 
applied to multiple comparisons. Time-to-event analyses were plotted using Kaplan-
Meier curves and assessed using Log Rank (Mantel-Cox) calculations. Receiver-
operator curves (ROC) were generated by plotting true positive rates against the 
false positive rates. Prior to analysis, cases were classified into binary groups 
depending on the variable of interest (e.g. high/low-grade epithelial dysplasia; 
normal/abnormal EGFR GCN; high/low EGFR protein expression (i.e. above or 
below mean proportion of positive cells for the normal epithelium). Ordinal data were 
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analysed using Pearson’s Chi-squared test. Results were considered significant at 
p<0.05. 
Ethical approval 
The study had a favourable ethical opinion from the National Research Ethics 
Service (NRES) Committee North East, Sunderland (REC reference: 11/NE/0118). 
Results 
Patient characteristics and clinical outcomes 
A total of 78 OPMD and 92 OSCC cases satisfied the study inclusion criteria. Mean 
ages for these two groups were 58.6 (range 30 - 94) and 61.8 years-old (range: 33 - 
93) respectively. Both had a male predominance (overall M:F - 1.54:1). Clinical 
outcomes and other characteristics are summarised in Supplementary Table 1 (see 
Supplementary Data). There was no correlation between the clinical outcome of 
OPMD/OSCC and either patient demographics (age, sex) or mucosal subsite (data 
not shown). 
For OPMD, the histological grade of epithelial dysplasia showed a significant 
correlation with clinical outcome. Cases with high-grade epithelial dysplasia were 
more likely to undergo malignant transformation than cases with low-grade epithelial 
dysplasia (p<0.05, Figure 2A). 
EGFR in situ hybridisation 
Nuclei in normal epithelium adjacent to OPMD or OSCC consistently showed 
disomy, the normal EGFR ISH signal (Figure 3 C). 
OPMD 
Low polysomy was detected in 15 OPMD cases (Figure 3 I). Eight of these cases 
underwent malignant transformation. One OPMD case displayed clustered signals 
consistent with EGFR genomic gain (Figure 3L). This case underwent malignant 
transformation after 17 months. 
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For statistical analysis, the 15 OPMD with low polysomy were combined with the one 
case of EGFR genomic gain to form a single ‘abnormal EGFR GCN’ group (n = 16). 
Kaplan-Meier time-to-event analysis demonstrated a statistically significant 
correlation between abnormal EGFR GCN and malignant transformation (p<0.0001, 
Figure 2B). Comparison using receiver-operator curve (ROC) analysis confirmed that 
abnormal EGFR GCN was a more reliable predictor of malignant transformation than 
high-grade epithelial dysplasia (Figure 4). A combined category (cases with both 
abnormal EGFR GCN and high-grade epithelial dysplasia) showed similar Kaplan-
Meier curves to EGFR GCN alone (Figure 2C) and the ROC profile was identical 
(data not shown). 
OSCC arising from OPMD cases 
Twenty-two OPMD cases underwent malignant transformation to OSCC. Biopsy 
material was available for 21 of these cases. EGFR genomic gain was detected in 
nearly one-quarter of the associated OSCC (5 cases, 24.0%). One-third of the 
associated OSCC showed low polysomy (7 cases, 33.3%). The associated OSCC 
generally either maintained the low polysomy of the OPMD, or showed progression 
to EGFR genomic gain. The EGFR GCN categories of the transforming OPMD and 
associated OSCC are shown in Figure 5.  
Early-stage OSCC 
EGFR genomic gain was identified in 23 (24.7%) early-stage OSCC (11 showed high 
polysomy and 12 showed clusters). EGFR genomic gain was associated with a 
reduction in mean overall survival time (50.2 months vs. 57.7 months for cases with 
no genomic gain) and disease-free survival (45.6 months vs. 47.7 months for cases 
with no genomic gain); however, neither trend was statistically significant (p=0.201 
and p=0.472, respectively). EGFR genomic gain did not correlate with tumour grade, 
recurrence or lymph node metastasis (data not shown). 
EGFR protein expression 
OPMD 
Areas of epithelial dysplasia showed significantly higher mean EGFR protein 
expression than normal epithelium (Figure 6). There was also a correlation between 
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EGFR protein expression and grade of epithelial dysplasia: OPMD with high-grade 
epithelial dysplasia had significantly higher levels of EGFR-positive cells than OPMD 
with low-grade epithelial dysplasia (Figure 6). However, the level of EGFR protein 
expression did not correlate with malignant transformation (Figures 2D and 6). 
OSCC arising from OPMD cases 
The OSCC associated with the transformed group of OPMD showed significantly 
higher mean EGFR protein expression than normal epithelium (p<0.0001, 
Independent T-test). 
Early-stage OSCC 
Early-stage OSCC had significantly higher mean EGFR protein expression than 
normal epithelium (Figure 6); however, EGFR expression did not correlate with 
tumour grade, stage, or clinical outcome (data not shown). 
Correlation between EGFR gene copy number and protein expression 
EGFR protein expression was significantly higher in OPMD with an abnormal EGFR 
GCN than cases with normal EGFR GCN (abnormal EGFR GCN mean - 49.9%, s.d. 
12.1 vs. normal EGFR GCN mean - 29.3%, s.d. 15.7; p<0.0001). EGFR protein 
expression was significantly higher in OSCC with EGFR genomic gain relative to 
cases with no genomic gain (EGFR genomic gain mean - 51.2%, s.d. 21.9 vs. no 
genomic gain mean - 35.9%, s.d. 22.5; p<0.01).  
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Discussion 
There is a continuing need for biomarkers that refine morphological diagnoses and 
inform clinical decisions for patients with OPMD and OSCC (9). EGFR GCN is used 
in the prognostication of non-small cell lung carcinoma (10, 11) and to predict 
response to EGFR-targeted chemotherapeutic agents (12). Over recent years, 
EGFR GCN has emerged as a potential biomarker for OPMD and OSCC (30, 32). 
However, the prevalence and clinical significance of EGFR GCN abnormalities in 
OPMD and OSCC are not well defined (20, 21, 33, 34). Furthermore, it is unclear 
how criteria validated for interpretation of EGFR GCN signals in non-small cell lung 
carcinoma should be applied to oral cancer. It is well-documented that detection of 
high-risk human papillomavirus (HPV) by p16 immunohistochemistry (IHC) and in 
situ hybridisation (ISH) is significant in the prognostication of oropharyngeal 
squamous cell carcinoma (35-37). The current study was restricted to the 
examination of potentially malignant disorders/squamous cell carcinoma of the oral 
cavity and excluded oropharyngeal subsites. Consequently, we would only expect a 
very small number of cases to harbour oncogenic HPV infection, less than 5% (38, 
39). HPV status was therefore unlikely to influence the results of our study. 
One-fifth of OPMD in the present study showed an abnormal EGFR GCN, but only 
one case showed evidence of EGFR genomic gain according to the criteria validated 
for non-small cell lung cancer. This is consistent with data from studies of EGFR 
GCN in OSCC, which indicate that EGFR genomic gain is a late event in oral 
carcinogenesis (23-25). It is striking, however, that the majority of OPMD with low 
polysomy progressed to OSCC. This finding is consistent with two recent studies that 
suggest low polysomy is an early feature of OPMD destined to undergo malignant 
transformation, one which heralds EGFR genomic gain later in oral carcinogenesis 
(27, 28). Both studies used fluorescence ISH (FISH) rather than the chromogenic 
ISH (CISH) technique used in the current study. Benchekroun et al (27) studied 
EGFR FISH in a subset of 49 OPMD, applying a definition of FISH positivity that 
encompassed all EGFR GCN abnormalities, including trisomy and low polysomy. 
While only one case showed evidence of EGFR genomic gain, a further 41% of 
cases showed FISH positivity using their modified classification. FISH-positive 
OPMD had significantly higher rates of malignant transformation compared to diploid 
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cases. A recent study of 20 OPMD by Poh et al (28) also supports the application of 
a lower threshold for classifying EGFR GCN as abnormal: although only one case 
showed EGFR genomic gain, any increase in EGFR GCN was strongly associated 
with an increased risk of malignant transformation, irrespective of whether the EGFR 
GCN increase was low or high; increased EGFR GCN was also associated with a 
reduced time to malignant transformation (28). Together, these studies suggest that 
EGFR GCN may have some clinical utility in the risk management of OPMD, but is 
not sufficiently predictive to be used as a standalone biomarker. 
Although the frequency of EGFR mutations documented in OSCC is low (40-42) , it 
is a limitation of the current study that neither EGFR mutation status nor downstream 
EGFR targets were evaluated. It is possible that EGFR GCN represents a ‘surrogate’ 
marker for other genetic and molecular abnormalities and simply reflect 
chromosomal instability; nevertheless, the positive correlation between EGFR GCN 
and protein over-expression suggests that increased EGFR GCN may be 
functionally relevant. Data from the group of OSCC that transformed from OPMD 
provide some evidence to support this hypothesis: the majority of these OSCC either 
maintained the abnormal EGFR GCN of the index OPMD or progressed to EGFR 
genomic gain, suggesting that EGFR genetic abnormalities accumulate during oral 
carcinogenesis. Interestingly, however, two cases of OPMD with abnormal EGFR 
GCN produced OSCC with a normal EGFR ISH signal. This may reflect clonal 
evolution of carcinoma from malignant cells with normal EGFR GCN; alternatively, it 
may simply represent tumour heterogeneity and the consequent limitations of 
sampling. 
A quarter of OSCC in the present study showed EGFR genomic gain. This finding 
was consistent across both the early-stage and transformed OSCC groups. It is 
higher than the 9% rate reported in a tissue-microarray study by Rössle et al (24). 
This earlier study also focused on early-stage (stage I/II) OSCC; however, it was 
limited by assessment of 0.6mm diameter tissue cores. It is our experience that the 
EGFR ISH pattern in OSCC is heterogeneous; tissue microarray sampling may 
therefore not correlate with measurements taken from whole sections. 
Notwithstanding these issues, however, the proportion of cases with EGFR genomic 
gain in the current study is towards the lower end of the range of values reported to 
date (range 9% to 56%) (23-26). 
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Our study did not identify a significant correlation between EGFR genomic gain and 
clinical outcome in OSCC, which is similar to two recent studies (24, 43). By 
contrast, Temam et al (20) reported a 9% 5-year survival rate for patients with EGFR 
genomic gain compared with 71% 5-year survival rate for patients with no genomic 
gain. Although the study used quantitative real-time PCR, its findings have been 
corroborated by other studies using FISH (21, 23). This apparent discrepancy may 
reflect the inclusion of late-stage OSCC in these previous studies; our study differed 
in its focus on the transition from OPMD to OSCC and assessment of early-stage 
OSCC. 
Our data confirm that EGFR protein expression is increased in the majority of OPMD 
and OSCC (44-46). The ubiquity of EGFR over-expression highlights a likely 
important role in oral carcinogenesis, but limits its clinical utility as a biomarker for 
stratifying patient management. In OPMD, EGFR protein expression was less 
predictive of clinical outcome than grade of epithelial dysplasia. It is possible that 
increased EGFR protein expression represents a bystander change, reflecting but 
not driving tumour progression, which may account for the lack of correlation with 
disease-specific clinical outcomes (29, 30, 47). 
There is evidence to suggest that EGFR GCN may help to predict the response of 
head and neck cancers to EGFR-targeted agents. For example, EGFR genomic gain 
has been shown to predict which patients have an increased likelihood of response 
to erlotinib therapy (33). The present study was not designed to investigate response 
to EGFR-targeted agents or other clinical interventions. None of the patients 
received EGFR-targeted therapy and the OPMD group was heterogeneous, 
including cases managed by surveillance and laser excision (48). Despite these 
limitations, our data support the view that a subgroup of OPMD and OSCC harbour 
EGFR GCN abnormalities and have increased EGFR protein expression; however, 
whether these lesions have a differential response to EGFR-targeted agents or other 
therapies remains to be tested. 
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Conclusion 
This study highlights the potential clinical utility of EGFR GCN assessment for 
predicting malignant transformation in OPMD. EGFR GCN abnormalities are more 
reliably predictive of malignant transformation than the histological grade of epithelial 
dysplasia. EGFR genomic gain is present in a quarter of early-stage OSCC, but does 
not correlate with their clinical outcomes. OSCC derived from OPMD generally either 
maintained the abnormal EGFR GCN of the index OPMD, or progressed to EGFR 
genomic gain. This suggests that, in a subset of cases, EGFR has an oncogenic 
function during oral carcinogenesis. Further studies are required to verify these 
findings and to determine whether EGFR GCN predicts the response of OPMD and 
OSCC to EGFR-targeted therapies. 
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Figure 1 Interpretation of dual EGFR gene and chromosome 7 in situ 
hybridisation signal 
Adapted from ‘Interpretation Guide, Ventana Inform EGFR DNA Probe: DNA Probe Staining 
of Non-Small-Cell Lung Carcinoma’ (31). (Used with manufacturer’s permission. Full 
copyright © 2015 Ventana Medical Systems, Inc.) 
 
Figure 2 Kaplan-Meier time-to-event analysis showing malignant 
transformation in OPMD stratified according to grade of epithelial dysplasia, 
EGFR gene copy number, and EGFR protein expression 
Blue line: A) Low-grade epithelial dysplasia; B) Normal EGFR GCN; C) Low-grade epithelial 
dysplasia & normal EGFR GCN combined; D) Low EGFR protein expression 
 
Green line: A) High-grade epithelial dysplasia; B) Abnormal EGFR GCN; C) High-grade 
epithelial dysplasia & abnormal EGFR GCN combined; D) High EGFR protein expression 
 
A) There was a significant correlation between high-grade epithelial dysplasia and malignant 
transformation (p<0.05, Chi2 value = 4.974, 1 d.f.). 
B) There was a significant correlation between abnormal EGFR GCN and malignant 
transformation (p<0.0001; Chi2 value = 13.929, 1d.f.). 
C) A similar correlation was identified when epithelial dysplasia and EGFR GCN categories 
were combined (p<0.0001; Chi2 value = 16.069, 1d.f.). 
D) There was no correlation between EGFR protein expression and malignant 
transformation (p=0.356). 
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Figure 3 EGFR protein expression and EGFR in situ hybridisation for 
normal mucosa and OPMD with low-grade and high-grade epithelial dysplasia 
A) Normal mucosa. B) In normal squamous epithelium, EGFR protein is expressed most 
strongly in the basal and parabasal layers, but is lost towards the surface. C) Nuclei of 
keratinocytes show disomy by in situ hybridisation. D) OPMD with low-grade epithelial 
dysplasia. E) EGFR protein expression is increased in low-grade epithelial dysplasia relative 
to normal squamous epithelium. Expression is most noticeably stronger in the prickle layer. 
F) However, nuclei of keratinocytes still show disomy by in situ hybridisation. G) OPMD with 
high-grade epithelial dysplasia. H) EGFR protein expression is increased in high-grade 
epithelial dysplasia relative to both normal squamous epithelium (B) and low-grade epithelial 
dysplasia (E). Expression is strong throughout the full thickness of the epithelium. I) In this 
example of high-grade epithelial dysplasia nuclei of keratinocytes show an abnormal signal, 
low polysomy, by in situ hybridisation. J) OPMD with high-grade epithelial dysplasia. K) 
There is strong full-thickness expression of EGFR protein. L) This example of high-grade 
epithelial dysplasia shows a clustered nuclear signal by in situ hybridisation. 
 
H&E and EGFR IHC x100 magnification; EGFR ISH x400 original magnification. 
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Figure 4 Receiver-operator curve analysis of malignant transformation for 
high-grade epithelial dysplasia and abnormal EGFR gene copy number 
Red line: abnormal EGFR gene copy number. Green line – high-grade epithelial dysplasia. 
Black line – reference line. 
 
The table beneath the chart summarises the differences between the two curves. The 
greater the area beneath the curve, the greater the predictive reliability of the marker. The 
area beneath the curve for abnormal EGFR GCN was greater than the area for high-grade 
epithelial dysplasia. This indicates that abnormal EGFR GCN was more reliably predictive of 
malignant transformation than high-grade epithelial dysplasia. This is further borne out by 
comparison of the asymptotic significance of the two tests: only abnormal EGFR GCN is 
significant at p<0.05. 
 
Figure 5 EGFR GCN of OPMD that underwent malignant transformation 
and their associated OSCC 
Green – normal GCN; amber – low polysomy; red – genomic gain. 
 
Figure 6 Comparison of EGFR protein expression for normal epithelium, 
OPMD and early stage OSCC 
Areas of epithelial dysplasia and early-stage OSCC had significantly higher EGFR 
expression than normal epithelium (p<0.001 and p<0.0001 respectively). OPMD with high-
grade epithelial dysplasia had significantly higher levels of EGFR than OPMD with low-grade 
epithelial dysplasia (p<0.0001). There were no significant differences in the EGFR protein 
expression of OPMD that underwent malignant transformation and those which did not 
(p>0.05). The error bars show the standard error of the mean. 
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
EGFR GCN Diagnostic 
category 
Cellular 
appearance 
Disomy Normal  
Trisomy Low polysomy 
Low polysomy  
>4 copy < 40% cells 
Low polysomy 
High polysomy  
>4 copy > 40% cells 
Genomic gain 
Clusters Genomic gain  
EGFR > 15 copies  
> 10% cells 
Genomic gain 
Figure 1. 
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
A B 
EGFR protein expression 
EGFR gene copy number 
Combined: high-grade epithelial 
dysplasia & abnormal EGFR GCN 
Grade of epithelial dysplasia 
C D 
Time to Malignant Transformation (months) Time to Malignant Transformation (months) 
Time to Malignant Transformation (months) Time to Malignant Transformation (months) 
M
a
lig
n
a
n
t 
T
ra
n
s
fo
rm
a
ti
o
n
 
M
a
lig
n
a
n
t 
T
ra
n
s
fo
rm
a
ti
o
n
 
M
a
lig
n
a
n
t 
T
ra
n
s
fo
rm
a
ti
o
n
 
M
a
lig
n
a
n
t 
T
ra
n
s
fo
rm
a
ti
o
n
 
Figure 2. 
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
EGFR IHC H & E 
Normal 
mucosa 
Low-grade 
dysplasia  
High-grade 
dysplasia 
High-grade 
dysplasia 
G H 
A 
F E 
I 
D 
B C 
L K J 
EGFR ISH 
Figure 3. 
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
Test Variable 
Area beneath 
curve 
Standard error 
Asymptotic 
Significance 
Asymptotic 95% Confidence 
Interval 
Lower Upper 
High-grade 
epithelial 
dysplasia 
0.61 0.069 p>0.10 0.48 0.75 
Abnormal EGFR 
GCN 
0.64 0.074 p<0.05* 0.50 0.79 
Figure 4. 
Reference 
line 
Abnormal 
EGFR GCN 
High grade 
epithelial 
dysplasia 
Key 
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
Index OPMD Associated OSCC 
Figure 5. 
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
05
10
15
20
25
30
35
40
45
50
Normal mucosa OPMD Early-stage
OSCC
Low-grade High-grade No malignant
transformation
Malignant
transformation
n.s. 
% 
Figure 6. 
p<0.001 
p<0.0001 
p<0.0001 
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
 Published OnlineFirst April 8, 2016.Cancer Epidemiol Biomarkers Prev 
  
Timothy Bates, Matthew Kennedy, Ameena Diajil, et al. 
  
Number During Oral Carcinogenesis
Changes in Epidermal Growth Factor Receptor Gene Copy
  
Updated version
  
 10.1158/1055-9965.EPI-15-0949doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://cebp.aacrjournals.org/content/suppl/2016/04/08/1055-9965.EPI-15-0949.DC1.html
Access the most recent supplemental material at:
  
Manuscript
Author
edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
.permissions@aacr.orgDepartment at
To request permission to re-use all or part of this article, contact the AACR Publications
on April 10, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 8, 2016; DOI: 10.1158/1055-9965.EPI-15-0949 
 1 
 
Supplementary Table 1 Characteristics of OPMD and early-stage OSCC groups 
Characteristic Number (%) 
Oral potentially malignant disorders (n = 78) 
Mucosal Subsite: 
Tongue 
Floor of mouth 
Buccal mucosa 
Masticatory mucosa 
 
36 (46.1) 
29 (37.2) 
5 (6.4) 
8 (10.3) 
Histological Grade of Dysplasia: 
High-grade 
Low-grade 
 
44 (56.4) 
34 (43.6) 
Clinical Outcome: 
No malignant transformation 
Malignant transformation to OSCC 
 
56 (71.8) 
22 (28.2) 
Early-stage oral squamous cell carcinomas (n = 92) 
Mucosal Subsite 
Tongue 
Floor of mouth 
Buccal mucosa 
Masticatory mucosa 
 
49 (53.3) 
20 (21.7) 
9 (9.8) 
14 (15.2) 
pStage 
pStage I 
pStage II 
 
75 (81.5) 
17 (18.5) 
Histological Grade of Differentiation 
Well differentiated 
Moderately differentiated  
Poorly differentiated 
 
20 (21.6) 
63 (68.5) 
9 (9.9) 
Overall Survival 
Alive 
Free from disease 
With disease 
Deceased 
Free from disease 
With disease 
 
 
66 (71.7) 
1 (1.1) 
 
15 (16.3) 
10 (10.9) 
 
 
